Panelists discuss how the RELATIVITY-047 trial data highlights the efficacy of nivolumab plus relatlimab in managing advanced melanoma, offering improved progression-free survival with a favorable safety profile compared to with nivolumab alone.
Health Professionals
Tumor-targeted responsive nanoparticles for MRI and therapy
Manganese oxide nanoparticles (Mn3O4 NPs) were synthesized and modified with an LHRH-targeting peptide or anti-melanoma antibodies (cancer-targeting moieties), as well as an MMP2 cleavable peptide (a possible chemotactic agent). Nanostructured lipid carriers (NLCs) were employed to entrap the BRAF inhibitor vemurafenib and enhance the drug’s cytotoxicity.
Predictive Tool for Melanoma Could Guide Immunotherapy Choices
Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma.
New Study Identifies Effective Treatments for Melanoma-Associated Leptomeningeal Disease
In an interview, Vincent Law, of Moffitt Cancer Center, discussed a new study that offers hope for patients with melanoma brain metastasis.